{"filings":[{"id":861331,"accession_number":"0001193125-26-257423","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-06-04T20:15:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amended 2024 equity plan with 3.23M share increase and modified evergreen provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved one-time increase of 3,231,638 shares (approx. 8% of outstanding) to the 2024 Equity Incentive Plan.","Annual evergreen provision amended: fixed cap of 2,407,100 shares removed; future annual increase set at 5% of outstanding shares beginning FY2027.","Directors R. Michael Carruthers, Valerie M. Jansen, and Edward T. Mathers elected as Class II directors until 2029.","Shareholders ratified KPMG LLP as independent auditor for fiscal year ending Dec. 31, 2026.","Incentive stock option limit under plan set at 8 million shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94290,"accession_number":"0001193125-26-206396","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.","Cash and cash equivalents $192.1M as of March 31, 2026, including $150M private placement closed on March 31, expected to fund operations into 2029.","Announced nomination of OKI-355 for vascular anomalies and OKI-345 for breast cancer; IND submissions planned for first half 2027.","Company will not independently pursue further clinical development of OKI-219; data from PIKture-01 study to be reported by end of 2026.","R&D expenses $11.7M (down from $13.0M), G&A $3.9M (down from $4.0M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106530,"accession_number":"0001193125-26-130283","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.","Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).","IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.","Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.","Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106529,"accession_number":"0001193125-26-104104","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.","Cash and equivalents $59.1M as of Dec 31, 2025.","PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.","Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.","R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122874,"accession_number":"0001193125-25-269652","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OnKure enters ATM offering agreement with Leerink Partners; up to 3% fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Leerink Partners for at-the-market offering of Class A common stock.","Compensation set at 3.0% of gross proceeds from sales of Placement Shares.","No minimum offering amount; company may suspend sales at any time.","Sales commence only after SEC registration statement becomes effective.","Agreement contains customary representations, warranties, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122873,"accession_number":"0001193125-25-269468","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.","Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.","First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.","Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.","Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139567,"accession_number":"0001193125-25-178978","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.","Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.","Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.","New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.","New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157146,"accession_number":"0000950170-25-090403","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OnKure Therapeutics posts updated corporate presentation to IR website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["OnKure posted an updated corporate presentation on June 26, 2025.","Presentation is furnished as Exhibit 99.1 to Form 8-K.","No specific financial or operational details are provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157145,"accession_number":"0000950170-25-078375","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"OnKure shareholders elect Manke and Saccomano as Class I directors, ratify KPMG as auditor for FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Isaac Manke elected with 4,589,481 for, 882,303 withheld; Dr. Nicholas Saccomano with 5,209,380 for, 262,404 withheld.","KPMG LLP ratified as independent auditor for fiscal year ending December 31, 2025 (6,750,408 for, 111,715 against, 208 abstain).","Both directors will serve until the 2028 annual meeting of stockholders.","Broker non-votes totaled 1,390,547 for each director proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157144,"accession_number":"0000950170-25-063969","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.","Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.","PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.","Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.","Pan-mutant PI3Kα development candidate to be announced in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175503,"accession_number":"0000950170-25-036306","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.","Cash and equivalents $110.8M; expected to fund operations into Q4 2026 through multiple clinical readouts.","PIKture-01 Part A monotherapy enrollment near complete; PK and preliminary efficacy data expected H2 2025.","Part B fulvestrant combination dosing initiated through 900 mg BID cohort; initial data due H2 2025.","Pan-mutant PI3Kα development candidate to be announced in Q2 2025; aims for ~10x selectivity over wild type."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192453,"accession_number":"0000950170-24-134757","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.","Only Grade 1 TRAEs reported (diarrhea, nausea, pruritus); no hyperglycemia observed.","900 mg BID achieved steady-state PK with near-continuous EC80 coverage for pAKT inhibition.","Two HR+/HER2- breast cancer patients on 300 mg showed >7 months stable disease; one had >95% ctDNA reduction.","Part 1b evaluating OKI-219 + fulvestrant initiated; single-agent/combination data expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192452,"accession_number":"0000950170-24-123265","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.","Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.","Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.","Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.","Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192451,"accession_number":"0001193125-24-234487","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["2.01","3.02","9.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"status":"ready","headline":"OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.","PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M.","Reverse stock split 1:10, name change to OnKure Therapeutics, ticker changes from RPHM to OKUR.","Lead candidate OKI-219 (PI3Kα H1047R inhibitor) in Phase 1; early data expected Q4 2024.","New board and management: Nicholas Saccomano CEO, Samuel Agresta CMO, Jason Leverone CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192454,"accession_number":"0001193125-24-231281","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Reneo stockholders approve all proposals for OnKure merger at special meeting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposal 1 (stock issuance for merger) approved: 21.87M for, 110.6K against.","Proposal 2 (PIPE stock issuance >20%) approved: 21.87M for, 110.7K against.","Proposal 4 (reverse stock split) approved: 21.85M for, 131.9K against.","Proposals 5 and 6 (NewCo equity plans) approved by 17.48M and 18.38M votes for.","All seven proposals passed; adjournment not needed as quorum and votes were sufficient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208922,"accession_number":"0001193125-24-222429","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.","Reneo denies allegations but voluntarily supplements proxy with details on Leerink's $40k prior compensation and 5% aggregate placement agent fee.","Supplemental disclosures include unadjusted OnKure forecasts showing projected net sales up to $3B by 2042 and DCF equity value range of $180M-$290M.","Reneo confirms no internal liquidation analysis was prepared; board relied on OnKure forecasts and $15M enterprise value ascribed to Reneo.","Merger and concurrent PIPE expected to close; company intends to vigorously defend against litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208921,"accession_number":"0001193125-24-218879","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.","Termination linked to planned merger with OnKure, Inc. and cessation of drug development.","Hall will receive severance benefits under previously disclosed severance plan.","Merger with OnKure is expected to shift company away from historical drug development.","Gregory J. Flesher remains CEO; no replacement for CDO announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208920,"accession_number":"0000950170-24-096127","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.","R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.","Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.","General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226736,"accession_number":"0001193125-24-136785","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.","Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.","OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).","Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.","Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226735,"accession_number":"0000950170-24-054442","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.","Suspended all mavodelpar development; reduced workforce by ~90% in Dec 2023 and Feb 2024.","Retained independent financial advisor to explore strategic alternatives, including possible sale.","Q1 2024 net loss $8.4M ($0.25/share) vs $15.1M ($0.60/share) Q1 2023; cash $82.8M as of Mar 31, 2024.","R&D expenses fell to $4.9M from $11.0M due to program suspension and cost-cutting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245690,"accession_number":"0000950170-24-038003","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo's pivotal STRIDE study misses endpoints; company cuts 90% workforce, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STRIDE trial of mavodelpar in primary mitochondrial myopathy failed primary and secondary efficacy endpoints.","Company suspended all mavodelpar development and reduced workforce by approximately 90%.","Q4 2023 net loss $23.6M ($0.70/share); full-year net loss $77.4M ($2.52/share).","Cash, equivalents, and short-term investments $103.0M at Dec 31, 2023; expects ~$82.0M at March 31, 2024.","Retained independent financial advisor to evaluate strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245689,"accession_number":"0000950170-24-019338","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second workforce reduction of approximately 20% to be completed by February 29, 2024.","Estimated $1.7 million in cash severance and employee termination costs in Q1 2024.","Follows prior reduction announced December 14, 2023 as part of cost-saving plan.","Actual charges may differ due to assumptions and potential additional costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263161,"accession_number":"0001193125-23-295039","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.","Company suspends all mavodelpar development including STRIDE AHEAD; workforce reduced ~70%.","Estimated Q4 2023 charges of ~$2.5M for severance and termination-related costs.","Company has >$100M in cash, cash equivalents, and short-term investments to fund operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263160,"accession_number":"0000950170-23-062888","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.","Cash, cash equivalents, and short-term investments of $125.6M as of September 30, 2023.","Topline results from pivotal STRIDE study in adult PMM patients expected in December 2023.","Repurchased 576,443 shares for $4.4M from vTv Therapeutics in October 2023; shares retired.","Enrolled 88% of eligible STRIDE patients in open-label extension; 65 patients treated beyond 52 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263159,"accession_number":"0000950170-23-056416","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Reneo Pharmaceuticals repurchases 576,443 shares from vTv Therapeutics for $4.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 576,443 shares at $7.64/share ($4.4M aggregate) from vTv Therapeutics LLC in a private transaction.","Common Stock Repurchase Agreement dated October 30, 2023, with no further repurchase commitments disclosed.","Repurchased shares will be retired or held as treasury stock, per standard practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263158,"accession_number":"0001193125-23-252984","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.","Over 85% of eligible patients enrolled in ongoing STRIDE AHEAD study.","Company to share data analysis with FDA in Q1 2024; NDA submission planned first half 2024.","STRIDE and STRIDE AHEAD studies to form basis of NDA submission to FDA and other regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280368,"accession_number":"0000950170-23-041275","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.","Cash and investments $142.7M as of June 30; raised $68.3M gross in May offering.","Topline data from pivotal mavodelpar STRIDE study in PMM due in Q4 2023.","Over 130 patients enrolled in STRIDE AHEAD OLE study; criteria expanded to nDNA defects.","R&D expenses $14.4M (up from $8.1M) driven by clinical and manufacturing costs for mavodelpar."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298906,"accession_number":"0000950170-23-026807","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Reneo shareholders elect three Class III directors, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected all three Class III director nominees: Mathers 15.75M for, Muralidhar 15.42M for, Seltzer 15.94M for; 3.76M broker non-votes each.","Ratified Ernst & Young as independent auditor for FY2023 with 20.32M votes for, 12.6K against, 100 abstain.","Record date April 10, 2023; 25,107,430 shares outstanding entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298905,"accession_number":"0000950170-23-021217","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.","Cash, equivalents, and short-term investments totaled $93.8M as of March 31, 2023.","Completed enrollment of pivotal STRIDE study (213 patients); topline results expected Q4 2023.","Raised $68.3M gross from public offering and private placement in May 2023.","Received FDA Fast Track designation for mavodelpar in long-chain fatty acid oxidation disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298904,"accession_number":"0001193125-23-137165","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.","Net proceeds expected approx. $58.2M after underwriting discounts and expenses.","Concurrent $5.0M private placement to Abingworth Bioventures at same $8.00/share, closing conditioned on public offering.","Offering expected to close May 8, 2023; shares sold under effective S-3 shelf registration.","Jefferies, BofA Securities, and Piper Sandler act as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298903,"accession_number":"0001193125-23-134386","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.","Non-binding term sheet for structured royalty financing up to $100M with an insider investor (>5% holder).","Initial $30M at closing, additional tranches based on milestones; deal expected Q2 2023 if definitive.","Collaboration agreement with affiliate development company; joint steering committee planned.","Mavodelpar (REN001) royalty payments would apply if approved in US or EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319087,"accession_number":"0000950170-23-009977","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.","Cash, equivalents & short-term investments $101.2M as of Dec 31, 2022.","R&D expenses $37.7M in 2022, up 34% due to STRIDE and STRIDE AHEAD studies.","Pivotal STRIDE study (PMM) enrolled target 200 patients; topline results expected Q4 2023.","Plans to study mavodelpar in PMM due to nDNA defects and advance LC-FAOD program into Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319086,"accession_number":"0000950170-23-007709","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.","STRIDE AHEAD long-term safety trial amended to enroll PMM due to mtDNA and nuclear DNA defects.","Topline data from STRIDE expected in Q4 2023; marketing applications planned for 2024.","STRIDE is a randomized, double-blind, placebo-controlled Phase 2b trial of 100 mg mavodelpar daily."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319085,"accession_number":"0001193125-23-067520","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Reneo Pharmaceuticals says SVB exposure immaterial; accounts hold minimal cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company maintains operating accounts at Silicon Valley Bank with minimal cash relative to total cash, cash equivalents and investments.","Believes any loss from SVB receivership is immaterial to its financial position.","No further details on total cash balance or contingency plans disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319084,"accession_number":"0001193125-23-004092","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Reneo posts updated corporate presentation for JP Morgan Healthcare Conference; no specific details available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on company website and furnished as Exhibit 99.1; filing does not include slide content.","No financial data, guidance, or pipeline milestones disclosed in the filing text.","Investors should review the presentation on Reneo's website for any material updates.","Ticker RPHM; event is routine conference participation with no immediate financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337315,"accession_number":"0000950170-22-023234","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.","Cash, equivalents & short-term investments total $116M as of Sept 30, 2022.","Over 80% enrollment in pivotal STRIDE study for PMM with mtDNA defects; topline data expected Q4 2023.","Positive Phase 1b results in LC-FAOD patients; planning Phase 2 study.","FDA and EMA confirmed positive data from STRIDE/STRIDE AHEAD could support registration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354680,"accession_number":"0000950170-22-016015","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.","Cash, cash equivalents, and short-term investments ~$127M as of June 30, 2022.","R&D expenses $8.1M (up $1.8M YoY); G&A $4.3M (up $1.4M).","Positive results from REN001 Phase 1b LC-FAOD study; plan to meet regulators.","STRIDE pivotal PMM study enrollment two-thirds complete; on track for year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354679,"accession_number":"0001193125-22-209391","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharmaceuticals appoints Roshawn Blunt as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roshawn Blunt appointed as Class I director effective August 2, 2022, term expiring at 2025 annual meeting.","She will receive $40,000 annual cash retainer and an initial option grant of 35,000 shares vesting over three years.","Further annual option grants of 17,500 shares, vesting by next annual meeting, with full acceleration on change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372685,"accession_number":"0001558370-22-009679","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Reneo shareholders elect Dube and Hoelscher as Class I directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting held June 1, 2022; total outstanding shares 24,458,550.","Eric M. Dube elected with 18,100,489 votes for, 795,195 against, 2,790,889 broker non-votes.","Paul W. Hoelscher elected with 18,877,021 votes for, 18,663 against, 2,790,889 broker non-votes.","Ratification of Ernst & Young as independent auditor for fiscal 2022 approved (21,675,242 for, 11,300 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372684,"accession_number":"0001558370-22-008096","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.","Cash, equivalents and short-term investments of $138.7M as of March 31, 2022.","R&D expenses rose to $9.3M from $5.5M, driven by STRIDE and FORWARD studies.","Enrolled 100th patient in STRIDE Phase 2b PMM trial; target enrollment 200.","Phase 1b and FORWARD natural history study results in LC-FAOD expected July 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391512,"accession_number":"0001558370-22-004156","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.","Cash, cash equivalents and short-term investments at Dec 31, 2021: $147.7M, sufficient into 2024.","STRIDE Phase 2b PMM study enrollment ongoing; data expected in 2023; LC-FAOD data in 2Q 2022.","REN001 in McArdle disease: no drug-related SAEs; company will not pursue Phase 2 for McArdle.","Appointed Ashley Hall as Chief Development Officer and Eric Dube to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391511,"accession_number":"0001193125-22-068011","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.","Cruse granted option for 25,000 shares vesting in 48 equal monthly installments; severance extended to 12 months post-change-of-control.","Jennifer P. Lam named principal financial and accounting officer effective March 31, 2022; base salary raised to $320K (from $309K).","Lam granted option for 10,000 shares vesting over 48 months; she previously served as VP of Finance & Administration since August 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391510,"accession_number":"0001193125-22-025697","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.","Separation agreement includes 9 months base salary severance ($385k/year), 12 months COBRA.","Equity vesting accelerated by 12 months; consulting engagement offered post-separation at $375/hour for 12 months.","No replacement CFO named; Jindal to continue service until separation date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391509,"accession_number":"0001193125-22-016015","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo appoints Paul Hoelscher to board and audit committee chair; two directors exit","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Hoelscher appointed Class I director and Audit Committee Chair, effective Jan 20, 2022.","Hoelscher receives $40k annual cash retainer plus $15k as Audit Committee Chair, and option for 35,000 shares vesting over 3 years.","Lon Cardon will not stand for re-election at 2022 annual meeting due to new role at Jackson Laboratory.","Kenneth Harrison resigned from board effective Jan 20 to focus on other endeavors; no disputes involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409708,"accession_number":"0001193125-21-367001","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharma CBO Wendy Johnson to depart Dec 31, enters consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Johnson will cease as CBO on Dec 31, 2021; will serve as consultant for 18 months.","Severance of $100k contingent on release of claims; continues base salary of $365k/yr until separation.","Equity awards continue to vest during consulting period; full acceleration if Company terminates without cause before June 30, 2023.","Cash consulting fee of $10k/month plus hourly rate for over 32 hours/month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409707,"accession_number":"0001558370-21-015672","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.","Cash, equivalents and short-term investments $157.7M as of Sept 30, 2021.","Initiated STRIDE Phase 2b trial for REN001 in PMM; completed LC-FAOD Phase 1b enrollment.","Appointed Ashley Hall as Chief Development Officer; received US patent notice of allowance for REN001 into 2041.","Expects Phase 1b results for McArdle disease Q1 2022 and LC-FAOD Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409706,"accession_number":"0001193125-21-296205","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharma appoints Ashley F. Hall as Chief Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.","Base salary $420,000, bonus up to 40%, housing reimbursement up to $5,000/month.","Relocation assistance of $150,000 if relocated within 18 months.","Equity inducement: option for 180,000 shares (4-yr vest) and RSU for 30,000 shares (vests on first NDA/MAA).","Severance: 9 months base/COBRA; on change in control 12 months plus full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428610,"accession_number":"0001558370-21-011217","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Reneo Pharmaceuticals posts updated corporate slide deck for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation available on company website and filed as Exhibit 99.1 to Form 8-K.","Deck highlights focus on rare genetic mitochondrial diseases.","No specific financial or clinical data disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428609,"accession_number":"0001558370-21-011209","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma Q2 net loss $9.2M vs $3.7M; cash $167.3M; STRIDE study first patient dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.43/share) for Q2 2021, compared to net loss of $3.7M ($1.82/share) in Q2 2020.","Cash, cash equivalents and short-term investments of $167.3M as of June 30, 2021.","First patient dosed in Phase 2b STRIDE trial of REN001 in primary mitochondrial myopathies (PMM); McArdle disease study enrollment completed.","R&D expenses increased to $6.3M from $2.8M; G&A expenses rose to $2.9M from $0.9M.","Anticipated milestones: McArdle results Q1 2022, LC-FAOD results H1 2022, FORWARD study results H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}